← All trials
NCT05451147
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 3, 2018
- Primary completion
- Apr 30, 2019
- Completion date
- Apr 30, 2019
- First posted
- Jul 11, 2022
- Last posted
- Jul 11, 2022
- Enrollment
- 48
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- A & U Tibbia CollegeLead sponsor
- A & U Tibbia CollegeOverall official - principal investigator
- A & U Tibbia CollegeReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.